Connect with us

Business

Johnson & Johnson Single-Shot Vaccine Safe in Trials: Report – TheStreet

Phase 1-2 trial of the Johnson & Johnson vaccine candidate generates an immune response in patients receiving the shot.

Published

on

post featured image
ADVERTISEMENT

Johnson & Johnson’s  (JNJ) – Get Report single-shot vaccine candidate has been shown to be safe and to generate a meaningful immune response in an early phase trial, according to a published report Wednesday.
A single shot of the vaccine “gives sustainable antibodies,” Dr. Paul Stoffels, chief scientific officer at J&J, told CNBC. The results have given the company “confidence” that the vaccine will be effective, Stoffels told CNBC.
The results of phase 1-2 trials were published Wednesday in the…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
New, more infectious ‘U.K.’ coronavirus variant confirmed in Louisiana, health officials say – The Advocate
post featured image
Forecast: Huge surf ahead of an approaching strong cold front – Hawaii News Now
post featured image
Parler CEO goes into hiding blaming Amazon flak, death threats – Pacifica Tribune